GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beximco Pharmaceuticals Ltd (LSE:BXP) » Definitions » Revenue

Beximco Pharmaceuticals (LSE:BXP) Revenue : £219.0 Mil (TTM As of Mar. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Beximco Pharmaceuticals Revenue?

Beximco Pharmaceuticals's revenue for the three months ended in Mar. 2024 was £75.4 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2024 was £219.0 Mil. Beximco Pharmaceuticals's Revenue per Share for the three months ended in Mar. 2024 was £0.17. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was £0.49.

Good Sign:

Beximco Pharmaceuticals Ltd has shown predictable revenue and earnings growth.

During the past 12 months, the average Revenue per Share Growth Rate of Beximco Pharmaceuticals was 11.00% per year. During the past 3 years, the average Revenue per Share Growth Rate was 15.30% per year. During the past 5 years, the average Revenue per Share Growth Rate was 16.60% per year. During the past 10 years, the average Revenue per Share Growth Rate was 16.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Beximco Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 24.70% per year. The lowest was -12.30% per year. And the median was 15.30% per year.


Beximco Pharmaceuticals Revenue Historical Data

The historical data trend for Beximco Pharmaceuticals's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beximco Pharmaceuticals Revenue Chart

Beximco Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 156.50 175.67 202.30 237.80 269.33

Beximco Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23 Mar24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 67.85 65.53 68.82 74.79 75.36

Competitive Comparison of Beximco Pharmaceuticals's Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Beximco Pharmaceuticals's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beximco Pharmaceuticals's Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beximco Pharmaceuticals's Revenue distribution charts can be found below:

* The bar in red indicates where Beximco Pharmaceuticals's Revenue falls into.



Beximco Pharmaceuticals Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was £219.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Beximco Pharmaceuticals  (LSE:BXP) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Beximco Pharmaceuticals Revenue Related Terms

Thank you for viewing the detailed overview of Beximco Pharmaceuticals's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Beximco Pharmaceuticals (LSE:BXP) Business Description

Traded in Other Exchanges
Address
19 Dhanmondi, Road No. 7, Dhaka, BGD, 1205
Beximco Pharmaceuticals Ltd is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from local sales.